Monoclonal Antibody

单克隆抗体

• 批准号: 8530392
• 负责人: Michel Gilliet
• 金额: $ 0.29万
• 依托单位: UNIVERSITY OF TX MD ANDERSON CAN CTR
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/8530392
• 关键词: Affinity; Angelica; Animals; Antibodies; Antibody Affinity; Antigens; Basic Science; Biochemistry; Biological Assay; Bone Marrow Transplantation; Cancer Center; Cancer Center Support Grant; Cancer Immunology Science; Cell Therapy; Cellular biology; Clinical Investigator; Clinical Research; Clinical Trials; Custom; Dental; Development; Diagnosis; Doctor of Medicine; Doctor of Philosophy; Feedback; Funding; Future; Goals; Grant; Growth; Guidelines; Hematologic Neoplasms; Home environment; Human Resources; Immunology; Laboratories; Laboratory Research; Liquid substance; Manuals; Medicine; Methodology; Mission; Molecular Biology; Monoclonal Antibodies; Mus; Nitrogen; Normal Cell; Peer Review; Play; Policies; Positioning Attribute; Price; Procedures; Production; Progress Reports; Protocols documentation; Provider; Publications; Reagent; Records; Reproducibility of Results; Research; Research Personnel; Research Project Grants; Resource Sharing; Resources; Role; Rosa; Screening procedure; Services; Signal Transduction; Sterilization; System; Techniques; Time; Translational Research; University of Texas M D Anderson Cancer Center; cancer cell; carcinogenesis; clinical Diagnosis; design; experience; hybridoma production; information gathering; insight; instructor; interest; medical schools; meetings; member; novel; operation; professor; programs; tissue culture; tool; tumor; tumor xenograft; web site

Monoclonal antibodies have become an essential tool in biochemistry, molecular biology, and medicine, and basic and clinical investigators have been using them widely for research, diagnosis, and clinical therapy. The Monoclonal Antibodies Facility (MABF) was formally established in 2003. Its main goal is to produce high-affinity antibodies in a high-throughput and effective manner, while concentrating on quality of product and service. The MABF minimizes extensive hands-on procedures and standardizes protocols to provide accurate results and reproducibility. Specific aims and long-term objectives are: 1) to produce high-affinity custom monoclonal antibodies for a wide range of research projects; 2) to enable investigators to access highly-experienced personnel in hybridoma production and methodologies, and trouble-shoot any antigen or screening-related issues; 3) to provide quality services at competitive prices; 4) to gain insight, by means of the generated antibodies, into the role that different molecules play in normal and pathological systems, and characterize them for eventual therapy or diagnosis. The MABF occupies 726 sq. ft. in SCRB 1, home to the Center for Cancer Immunology Research (CCIR) on the South Campus which is equipped with customized laboratory services, centralized tissue culture rooms, liquid nitrogen tanks rooms, and glassware washing and sterilization facilities, all of which are available to the MABF. The MABF staff consists of Michel Gilliet, MD, Core Leader, is responsible for the direction of the core and chairs the oversight committee. Dr. Gilliet meets with Dr. Bover and Long Vien regularly concerning the overall operation of the MABF. Laura Bover, PhD, Core Co-Leader, is responsible for the overall operation of the MABF, for progress reports, interest researchers in the use of the facility and assures that procedural and policy changes are vetted with the oversight committee. She is responsible together with Long Vien of the short- and long-term planning and growth of the facility. Long Vien, Core Manager, is responsible for the day-to-day operations of the core. Together with Dr. Bover, he plans and designs technical procedures for the different user requirements. James Wygant, Coordinator Research Laboratory, is responsible for technical procedures and makes the first contact with users. He records all activities of the facility and follows-up with users, gathering information pertaining to publications, and grants used to cover the services. Rosa Munoz, Research Assistant, is responsible for technical procedures (hands-on). Future plans are to redesign our website to provide more information on services and benefits in an effort to reach more researchers inside MDACC. The facility also needs to communicate more broadly about the unique value-added features of its services.

单克隆抗体已成为生物化学、分子生物学和医学领域的重要工具， 基础和临床研究人员已广泛将其用于研究、诊断和临床治疗。 单克隆抗体设施（MABF）于2003年正式成立。其主要目标是生产 以高通量、有效的方式生产高亲和力抗体，同时注重产品质量 和服务。 MABF 最大限度地减少了大量的实践程序并对协议进行了标准化，以提供 准确的结果和重现性。具体目标和长期目标是：1）产生高亲和力 适用于各种研究项目的定制单克隆抗体； 2) 使调查人员能够访问 在杂交瘤生产和方法学方面经验丰富的人员，并解决任何抗原或问题 筛查相关问题； 3）以有竞争力的价格提供优质的服务； 4）获得洞察力，通过 生成的抗体，了解不同分子在正常和病理系统中发挥的作用，以及 表征它们以用于最终的治疗或诊断。 MABF 位于 SCRB 1，占地 726 平方英尺，是 南校区癌症免疫学研究中心（CCIR）配备定制化设备 实验室服务、集中组织培养室、液氮罐室和玻璃器皿清洗 和灭菌设施，所有这些均可供 MABF 使用。 MABF 工作人员包括 Michel Gilliet、 MD，核心领导者，负责核心的指导并主持监督委员会。吉列特博士 定期与 Bover 博士和 Long Vien 会面，讨论 MABF 的整体运作情况。劳拉·博弗, 博士，核心联合领导者，负责 MABF 的整体运营、进度报告、兴趣 研究人员使用该设施，并确保程序和政策的变化经过 监督委员会。她与 Long Vien 一起负责短期和长期规划和 设施的增长。 Long Vien，核心经理，负责核心的日常运营。 他与 Bover 博士一起，针对不同的用户需求规划和设计技术程序。 James Wygant，研究实验室协调员，负责技术程序并制定 第一次接触用户。他记录了该设施的所有活动并跟踪用户，收集 有关出版物的信息以及用于支付服务的赠款。罗莎·穆尼奥斯，研究 助理，负责技术程序（实际操作）。未来的计划是重新设计我们的网站 提供有关服务和福利的更多信息，以便接触到 MDACC 内的更多研究人员。 该设施还需要更广泛地宣传其服务的独特增值功能。